BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
September ended the way it traded all month: split. Tech stocks clawed out a September gain while the Dow logged its worst month in years, Treasury yields marched to a 24-year high, and the Fed’s hiking cycle refused to die quietly. The afternoon’s biggest new development came from Washington’s drug regulators: on its PDUFA date, the FDA approved Bristol Myers Squibb’s Camzyos for children with a rare heart condition.
Here are the four stories that mattered most as markets closed out the third quarter.
1. Dow caps a bruising September as Treasury yields hit 24-year highs
Wall Street finished the final trading day of September on a split note. The Dow Jones Industrial Average fell nearly 0.9% to close around 50,906 — its lowest close since early June — while the S&P 500 slipped about 0.3% to 7,652 and the Nasdaq Composite added 0.2% to finish at 26,861.
The monthly scorecard was the real story: the Dow lost 4.3% in September, snapping a five-month winning streak, while the Nasdaq gained 1.9% and the S&P 500 shed 0.5%. For the quarter, the Dow fell 2.7% but the S&P 500 and Nasdaq each rose about 2%. Leadership was narrow — only five of the Dow’s 30 components finished September higher, while six of the seven Magnificent Seven stocks rose on the day, Meta being the lone laggard.
The bond market was the month’s villain. The 10-year Treasury yield closed at 5.29%, its highest level since 2002, and the average 30-year fixed mortgage rate hit 7.58%. Softer-than-expected August inflation — core PCE at 3.0% versus 3.3% expected — bought a morning rally that faded into the close, as investors turned their attention to whether the Fed’s October meeting brings another hike.
On that question, Goldman Sachs now says the softer PCE reading makes an October hike unlikely and pushes its call to December; prediction markets put October odds near 37%. Why it matters: with long rates at generational highs and mortgage rates above 7.5%, the third quarter’s gains belong almost entirely to mega-cap tech. That makes the upcoming Q3 earnings season the next real catalyst — either broadening the rally or exposing it.
- Dow September: -4.3% (worst month in years; Q3: -2.7%)
- Nasdaq September: +1.9%; S&P 500 September: -0.5%
- 10-year Treasury yield: 5.29% — highest since 2002
Related reading: August PCE Cools to 3.0% as Inflation Undershoots and GDP Jumps to 2.2% and 10-Year Treasury Yield Hits 5.30%, Highest Since 2002
2. FDA approves Camzyos for adolescents — the decision BMS investors were waiting for
On its September 30 PDUFA date, the FDA approved Camzyos (mavacamten) as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. The expanded indication covers pediatric patients ages 12 to under 18 who weigh at least 30 kg (about 66 pounds). Camzyos was first approved for adults in 2022.
Approval rested on the phase 3 SCOUT-HCM trial — a randomized, double-blind, placebo-controlled study of 44 adolescents — which showed a significant reduction in the Valsalva left ventricular outflow tract gradient versus placebo at 28 weeks. No patient saw left ventricular ejection fraction fall below 50%, and no deaths occurred during the study.
Why it matters: Camzyos is now the only cardiac myosin inhibitor approved for this younger population, giving Bristol Myers Squibb a pediatric label that competitors don’t yet have. The drug is already a growth engine for BMS — sales hit nearly $1.07 billion last year and jumped 74% year over year to $729 million in the first half of 2026 — at a time when patent expirations on legacy drugs are pressuring revenue.
- First CMI approved for adolescents with symptomatic oHCM (ages 12–17, at least 30 kg)
- SCOUT-HCM: 44 patients, 28 weeks, significant LVOT gradient reduction vs placebo
- Camzyos H1 2026 sales: $729M, up 74% year over year
3. World’s first currency-hedged bitcoin ETCs land in Europe
London-based HANetf has listed exchange-traded commodities that give bitcoin exposure while hedging currency swings — the world’s first currency-hedged crypto ETCs, with HSBC providing the hedges. The pound-hedged GBTC trades on the London Stock Exchange; the euro-hedged EBTC lists on Frankfurt’s Xetra and Euronext Paris.
The logic is simple: bitcoin is priced in dollars, so European investors carry unwanted dollar exposure alongside their crypto exposure. The new products target long-term bitcoin holders worried about dollar weakness. The structure mirrors currency-hedged gold ETCs, already a $23 billion asset class in Europe — roughly 13% of the continent’s gold ETC market — where HANetf already runs hedged products.
Why it matters: it’s another brick in crypto’s institutional wall. U.S. spot bitcoin ETFs have pulled in roughly $2.95 billion over the past 30 days despite bitcoin chopping sideways near $83,500 under the weight of 5.2%+ Treasury yields; bitcoin itself finished Wednesday’s session fractionally lower at about $83,566. Expect the European playbook — hedged, listed, custody-free — to keep expanding even as U.S. legislation stays stalled.
- World’s first currency-hedged crypto ETCs (GBTC in GBP, EBTC in EUR; HSBC hedging)
- U.S. spot BTC ETFs: roughly $2.95B in 30-day inflows despite BTC near $83,500
4. Oil wraps September with a 14% surge as diplomacy stalls and tankers get hit
Brent crude finished September up about 14% — its biggest monthly gain since July — after holding above $103 a barrel on Wednesday. WTI crude gained roughly 5.5% on the month, closing near $91.
Three forces stacked up. First, diplomacy: President Trump denied reports that Washington would ease Iran sanctions and release frozen Iranian funds in exchange for nuclear concessions, while Qatar’s shuttle diplomacy continued without a breakthrough. Second, security: midday Wednesday, the U.K. Maritime Trade Operations reported a vessel in the Strait of Hormuz was struck by an unknown projectile, reigniting tanker-risk premiums. Third, inventories: U.S. gasoline and distillate stocks fell even as crude stocks rose 922,000 barrels.
Why it matters: the market is torn. Physical flows are healing — Goldman Sachs estimates Gulf oil exports recovered to 23.3 million barrels per day over the past week, in line with the 2025 average — yet prices keep a fat geopolitical premium. OPEC+ meets Sunday, with sources pointing to November production targets being held unchanged. With Brent $10 higher on the month, energy is quietly the year’s loudest inflation risk.
- Brent +14% in September (biggest monthly gain since July)
- Trump denied Iran sanctions-relief reports; fresh projectile strike reported on a Hormuz tanker
- OPEC+ meets Sunday; November output targets expected unchanged
What do you think?
With the Dow down 4.3% in September and the Nasdaq up 1.9%, are we looking at a healthy rotation into tech — or a warning that the rally’s base is dangerously narrow? Share your take below.
Sources:
- Investor’s Business Daily — Stock Market Today
- Investopedia — Stocks End Mixed After Inflation Data
- InvestingLive — US Stocks Close Mixed
- FDA — Camzyos pediatric approval
- Bristol Myers Squibb — Expanded Camzyos indication
- Zacks — Can Camzyos’ Growth Offset BMS Patent Pressures?
- CoinDesk — HANetf/HSBC hedged bitcoin ETCs
- TradersUnion/Reuters — Oil markets rise on stalled U.S.-Iran talks
- Morningstar/OPIS — Nymex Overview: Oil, Products Jump
- WalletInvestor — Goldman pushes hike call to December
Auto-posted by the Bull Lounge news desk.
Not financial advice.
Log in to vote
